Grosclaude P, Menegoz F, Schaffer P, Macé Lesec'h J, Arveux P, Le Mab G, Soulié M, Villers A
Registre des cancers du Tarn, Albi, France.
Prog Urol. 1997 Sep;7(4):647-54.
To describe the epidemiological situation of prostatic cancer in France on the basis on a large population sample.
This study uses incidence data derived from French cancer registers, and mortality data obtained from death certificates. Crude rates and rates standardized for the world population are calculated. The variation of these rates is analysed by a log-linear model (adjusted for age, department and period).
The incidence of prostatic cancer in France in 1990 was 200 to 300/100,000 between the ages of 60 and 70 years and more than 600/100,000 after the age of 70 years. 73% of cases were diagnosed after the age of 70 years. The incidence increased annually by 8.76% between 1982 and 1990. An estimated 22,600 cases were diagnosed in France in 1990. The increased incidence of localized or local stages is due to the use of diagnostic tests (PSA and ultrasound-guided biopsies), as this increase accelerated after 1987. The crude mortality rate was 33.4/100,000 (384/100,000 between the ages of 75 and 85 years). It increased by 2.56% per annum from 1982 to 1990, but essentially for men over the age of 75 years.
These findings tend to make prostatic cancer a public health priority, but this affirmation must be moderated by the fact that this disease has a low impact on loss of life expectancy.
基于大量人群样本描述法国前列腺癌的流行病学情况。
本研究使用来自法国癌症登记处的发病率数据，以及从死亡证明中获取的死亡率数据。计算粗发病率和世界人口标准化发病率。通过对数线性模型（根据年龄、部门和时期进行调整）分析这些发病率的变化。
1990年法国60至70岁之间前列腺癌的发病率为每10万人200至300例，70岁以后超过每10万人600例。73%的病例在70岁以后被诊断出来。1982年至1990年间发病率每年增长8.76%。1990年法国估计有22,600例病例被诊断出来。局限性或局部阶段发病率的增加归因于诊断测试（前列腺特异性抗原和超声引导下活检）的使用，因为这种增加在1987年以后加速。粗死亡率为每10万人33.4例（75至85岁之间为每10万人384例）。1982年至1990年间每年增长2.56%，但主要是75岁以上的男性。
这些发现倾向于使前列腺癌成为公共卫生的优先事项，但这一论断必须因这种疾病对预期寿命损失影响较小这一事实而有所缓和。
